CHRONOGEN GETS APPROVAL TO START CHGN111 TRIAL

Chronogen has announced today that it has received approval from Health Canada to begin human clinical trials of one of their novel class of drugs called cellular oxidative stress modulators.

This Phase I/II study will assess the ability of a topical formulation of CHGN111 to prevent cutaneous phototoxicity induced by photodynamic therapy. The approval was based on extensive preclinical data and a complete manufacturing dossier.